eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Ferring Pharmaceuticals Ltd

Drayton Hall, Church Road, West Drayton, UB7 7PS, UK
Telephone: +44 (0)844 931 0050
Fax: +44 (0)844 931 0051
WWW: http://www.ferring.co.uk
Medical Information Direct Line: +44 (0)844 931 0054
Medical Information e-mail: medical@ferring.com
Medical Information Fax: +44 (0)844 931 0051

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 04/07/2008
SPC DDAVP Tablets 0.2mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 04/07/2008 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   16-May-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

In section 4.8 (undesirable effects), disorders including aggression in children......has been added.
Updated on 17/09/2007 and displayed until 04/07/2008
Reasons for adding or updating:
  • Change to section 6. 3 - Shelf Life
Date of revision of text on the SPC:   07/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

section 6.3: Shelf life extended from 2 to 3 years.
Updated on 22/05/2006 and displayed until 17/09/2007
Reasons for adding or updating:
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 10 (date of (partial) revision of the text
Date of revision of text on the SPC:   11/05/06
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 5.1 has been updated to include the EC50 value

Section 5.2 has been updated to include information on plasma concentration

Section 10 has been update to reflect the variation approval date.

Updated on 04/07/2003 and displayed until 22/05/2006
Reasons for adding or updating:
  • Change to section 9 - Date of Renewal of Authorisation
Updated on 10/06/2003 and displayed until 04/07/2003
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 05/08/2002 and displayed until 10/06/2003
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Updated on 09/08/2001 and displayed until 05/08/2002
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Updated on 15/05/2001 and displayed until 09/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 17/01/2001 and displayed until 15/05/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 17/01/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   desmopressin acetate